NEW YORK, May 4, 2020 /PRNewswire/ -- A new medical development is sweeping the country. Some may see it as controversial - but the studies don't lie. It's effective. So effective, in fact, that the FDA has just fast-tracked approval for research, meaning that it is aiming to gain a major stake in a key healthcare market that is on track to hit $260 billion in the next six years. And one company, in particular, is making exactly the right moves. Mentioned in today's commentary includes: Sage Therapeutics, Inc. (NASDAQ: SAGE), Cassava Sciences, Inc. (NASDAQ: SAVA), Aptose Biosciences Inc. (NASDAQ: APTO), Aeterna Zentaris Inc. (NASDAQ: AEZS), CRH Medical Corporation (NYSE: CRHM).
In the last 13 months, Champignon Brands (SHRM; SHRMF) now has taken a potential wonder drug from concept to product production for medical research. The name of this potential wonder drug is psilocybin, a natural compound found in mushrooms, and it could very well end up saving the life of someone you love.
Interest in psilocybin has exploded recently due to its potential to treat depression, post-traumatic stress disorder (PTSD), substance abuse and even to increase mental performance. This has attracted attention from high-level performers from Silicon Valley to Wall Street.
With bold plans to roll out treatment facilities in the U.S. by the end of 2020, Champignon Brands plans to own and control its own product vertical. Its goals and growth strategy dropped Champignon Brands directly within the $89 billion mental health sector. A sector whose time has come for disruption.
Rewriting The Playbook For Sector Change
The world is currently in the midst of a mental health crisis. Everything that could possibly go wrong, has. And to make matters worse, millions, if not tens of millions of people are stuck in isolation. It's never been more important to support the field of mental health. And the FDA seems to agree. Not only have they fast-tracked psilocybin, they've also approved other exciting new approaches to tackling mental health issues.
Take Sage Therapeutics (SAGE), for example. With a focus on new ways to treat mental health, the company released the only FDA-approved treatment for post-partum depression. It's drug, Zulresso, soared through clinical trials, and is advertised to help mothers feel better in just 2.5 days. The drug is administered under the careful guidance of professionals in their specialized treatment centers and has been a huge success for the company.
Cassava Sciences (SAVA) is another company taking an innovative approach to the treatment of mental health, specifically Alzheimer's disease. While its PTI-125 is still in its stage two of clinical trials, it's outlook is promising. The drugt aims to help treat the devastating Alzheimer's disease by bringing together different proteins to interact properly. So far it has been shown to improve the function of multiple brain receptors and exerts powerful anti-neuroinflammatory effects.
The first Champignon Brands acquisition was Artisan Growers, a British Columbia based craft mushroom cultivation, sourcing and supply operation focused on organic production. At Artisan Growers, the mushrooms are cultivated in special climate-controlled facilities that monitor moisture, humidity, light, airflow and temperature levels for optimal growth and quality.
Next on the acquisition list, Novo Formulations, a specialty biotechnology company, introduced Ketamine products and medical research IP into the Champignon Brands lineup. Ketamine, once used as a medication for starting and maintaining anesthesia, has seen a resurgence in recent years for its effectiveness as a rapid-acting antidepressant in research settings.
Whereas most antidepressants in the market today require 2-4 weeks before signs of improvements are seen, Ketamine demonstrates effectiveness within 1-2 days in some research trials.
With access to a purpose-built good manufacturing practice (GMP) and pharmaceutical (DIN) licensed facility in Quebec, Canada, and an accredited pharmacy in Ontario, Novo Formulations is working towards breakthroughs in ketamine, anesthetics and adaptogens and other natural molecules.
Surprisingly, the Ketamine introduction into the company wasn't the top story with the Novo Formulations acquisition. Part of Champignon Brands (SHRM;SHRMF) aggressive first mover strategy is emphasis on world-class team building. And that's exactly what they got with visionary and relentless innovator Dr. Joseph Gabriele, Ph.D.
Dr. Gabriele, a gifted molecular pharmacologist specializing in signal transduction within the central nervous system, brought exclusive formulations and patented intellectual property into the Champignon Brands stable.
Compile The Intellectual Property
Sometimes intellectual property IS the final product for biopharmaceutical companies. The giants of the industry build patent moats and branch out from there. Patents, partnerships and acquisitions are the name of the game in biotech..
Take Aptose Biosciences Inc. (APTO), for example. Aptose is a biotech company specializing in personalized therapies to address Canada's unmet oncology needs. The company uses genetic and epigenetic profiles to gain insights into certain cancers and patient populations in order to develop new treatments within the space.
Aptose has an exclusive partnership with Ohm Oncology to develop, manufacture and commercialize APL-581 in order to treat hematologic malignancies and related molecules. In late 2018, Aptose announced that it would be participating in a number of investor conferences, including January 7th's San Francisco-based Biotech Showcase 2019 to generate awareness and highlight their accomplishments.
Or AEterna Zentaris Inc. (AEZS). AEterna is a major biopharmaceutical up and comer. In 2018, the company saw steady growth, and an array of new developments over the course of the year. With a focus on oncology, endocrinology, and women's health solutions, AEterna has created a variety of new products, including Macrilen, the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency.
Recently, AEterna received European approval to market Macrillen which has pushed its value even higher. Dr. Christian Strasburger, the Head of Clinical Endocrinology at Charité Unversitaetsmedizin Berlin and the principal investigator for macimorelin explained, "Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition."
CRH Medical Corporation (CRHM) is another Canadian giant with a history of strong acquisitions. CRH specializes in products and services designed for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. With a long history within the space, CRH has positioned itself as a leader in the field, trusted by medical professionals all over the world.
CRH also made a majpr acquisition at the beginning of the year, buying out Anesthesia Care Associates, LLC, an Indiana-based gastroenterology anesthesia practice. The estimated $2.6 million deal will increase CRH's footprint in the space, and has been well received by investors.
Edward Wright , CEO of CRH, commented, "Anesthesia Care Associates extends our footprint to the state of Indiana , and once again shows the value of our existing O'Regan customer relationships." Now. Champignon is looking to follow a similar path. To strengthen its foothold in the psychedelic medicine sector, Champignon Brands next move was to acquire Tassili Sciences Corporation.
Tassili Sciences Corporation is partnered with the University of Miami and Miller School of Medicine to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries (mTBI) and posttraumatic stress disorder (PTSD).
Champignon Brands (SHRM;SHRMF) now owns 100% of the intellectual property, drug discovery and data accumulated by Tassili from the University of Miami and Miller School of Medicine research clinical trials.
The final acquisition, Altmed Capital Corp., gave Champignon Brands instant 75% controlling ownership of the Canadian Rapid Treatment Centre of Excellence (CRTCE), one of the world's leading Ketamine clinics. The acquisition also provided Champignon Brands with access to an additional $2,000,000 in cash as well as Altmed's substantial psychedelic medicine data and research IP.
Altmed, the clinic's operator, was founded and led by the brilliant Chief Executive Officer, Dr. Roger McIntyre.
One of the most cited academics in psychiatry, Dr. McIntyre has published the largest number of research articles most frequently cited by researchers globally in over 20 fields of science.
His belief that Big Pharma's antidepressants no longer work, referencing the bad side-effects and only working for some and not all patients. This belief led Dr. McIntyre to establish the CRTCE while focusing on Ketamine for its rapid impact on PTSD and depression.
Last year, the Canadian Rapid Treatment Centre of Excellence clinic delivered $1.5 million in revenue with gross margins upward of 50%.
Triple-Digit Upside Opportunities
Ownership of the silo and rollout of additional clinics in 2020 is intended to give Champignon Brands tremendous first mover advantage in the new psychedelic medicine sector, once it is legalized. Which means Champignon Brands (SHRM;SHRMF) could be first to build strong customer loyalty and brand recognition in the sector along with establishing market pricing for products.
By. Jorge Rodrigiez
**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
FORWARD-LOOKING STATEMENT. Statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense. Forward looking statements in this article include: that governments will legalize and regulate psychedelic medicine; that the worldwide functional mushroom markets combined will be worth $34.3 billion in gross sales in 2024; that Champignon Brands Inc. ("Champignon") can build an on-site research laboratory within the next 12-24 months; and rollout five additional clinics in the US by the end of 2020; can access the expertise of Champignon's acquisition targets' management teams to create and market depression and anxiety treatments; and that Champignon's business will be profitable. Forward-looking information is based on the opinions and estimates of Champignon at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Psychedelic medicine may not be legalized on the timeline as expected or at all; psychedelic medicine may not turn out to have as large a market as thought or be as lucrative as thought as a result of competition or other factors; Champignon may not be able to close on its announced acquisitions because of regulatory approval requirements or other reasons; that the acquisitions do not provide the expected benefits, business or expertise expected; that Champignon may not be as able to diversify or scale up as thought because of potential lack of capital, lack of facilities, regulatory compliance requirements or lack of suitable employees, partners or suppliers; none of Champignon's treatments have passed clinical trials or received FDA or other health authorities' approval; Champignon may not be able to raise funds and develop better treatments than competitors in the psychedelic medicine industry; actual operating performance of the facilities Champignon do not meet expectations; that competition quickly develops; that Champignon may not be able to retain key employees, partners and suppliers; costs may be higher than expected and profits therefore lower; and other risks affecting the Company in particular and the psychedelic medicine industry generally, including without limitation risks related to most agricultural crops, including crop failure and medical developments, including without limitation failure of human trials or rejection by medical regulators. The forward-looking statements in this document are made as of the date hereof and the Company disclaims any intent or obligation to update such forward-looking statements except as required by applicable securities laws.
PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Financialmorningpost.com, Joint Salty Holdings Corp., and their owners, managers, employees, and assigns (collectively, "we" or the "Company") has been paid by the profiled company to disseminate this communication. In this case the Company has been paid by Champignon seven thousand US dollars per month for market awareness including postins and articles. This compensation is a major conflict with our ability to be unbiased, more specifically:
This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by Champignon to conduct investor awareness advertising and marketing for [SHRM.V and SHRMTF.PK]. Financialmorningpost.com receives financial compensation to promote public companies. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of SHRM. The profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.
SHARE OWNERSHIP. The owner of Financialmorningpost.com owns shares of this featured company and therefore has an additional incentive to see the featured company's stock perform well. The owner of Financialmorningpost.com will not notify the market when it decides to buy more or sell shares of this issuer in the market. The owner of Financialmorningpost.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
LEGAL ADVISORY. Investing in companies associated with the psychedelic medicine industry may be illegal in the jurisdiction where a reader resides. Before investing in any public company involved in the psychedelic medicine industry, potential investors should check with their legal advisor as to whether an investment will breach local or federal law.
RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.
DISCLAIMER: Financialmorningpost.com (FMP) is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with Financialmorningpost.com or any company mentioned herein. The commentary, views and opinions expressed in this release by Financialmorningpost.com are solely those of Financialmorningpost.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact e-mail: firstname.lastname@example.org U.S. Phone: +1(954)345-0611